PERISINK ? Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

• Unité de recherche: INNOSUISSE
• Numéro de projet: 132.767 IP-LS
• Titre du projet anglais: PERISINK ? Control of the Peripheral sink and thus serum half-life of biologics via harnessing glycan-specific internalisation

Mots-clé (Anglais)

Life sciences, Biotechnology and processing

Résumé des résultats (Abstract) (Anglais)

InCephalo is a preclinical-stage biotech company developing innovative therapies for CNS diseases. This project focuses on advancing the C-Lock platform by developing glycan-optimized variants of biologics, enabling tunable systemic half-life without compromising activity.